Men and women between the ages of 30 and 80 years inclusive 2. Negative for anti-glutamic acid decarboxylase anti-GAD antibodies 4.
A1c at screening between 5. Negative pregnancy test at recruitment for all women with childbearing potential Exclusion Criteria: 1. Current anti-diabetic treatment with insulin, sulfonylurea, thiazolidinedione, alpha-glucosidase inhibitor, glucagon-like peptide-1 GLP-1 agonist or dipeptidyl peptidase-4 inhibitor 2. Type 1 diabetes or secondary forms of diabetes 3.
History of hypoglycemia unawareness or severe hypoglycemia requiring assistance 4. Hypersensitivity to insulin, metformin or the formulations of these products 6.
Description Summary: Background Metabolic surgery has beneficial metabolic effects, including remission of type 2 diabetes. We hypothesized that duodenojejunal bypass DJB surgery can protect against development of type 1 diabetes T1D by enhancing regulation of cellular and molecular pathways that control glucose homeostasis. At T1D diagnosis, a subcutaneous insulin pellet was implanted, oral glucose tolerance test was performed 21 days later, and tissues were collected 25 days after onset of T1D. Fecal microbiota composition was analyzed by 16S V4 sequencing. Results Postoperatively, DJB rats weighed less than sham rats
History of congestive heart failure 9. Unwillingness to administer insulin therapy or perform capillary blood glucose monitoring at least 4 times per day while receiving IIT Pregnancy or unwillingness to use reliable contraception.
Women should not be planning pregnancy for the duration of the study or the first 3 months after the study. Reliable contraception includes birth control pill, intra-uterine device, abstinence, tubal ligation, partner vasectomy, or condoms with spermicide.
Non-adherence to the induction phase or any factor likely to limit adherence to the study protocol, in the opinion of the investigator Nem:.